phenytoin has been researched along with dantrolene in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Ellis, RH; Leighton, M; Simpson, P; Tatham, P; Williams, J | 1 |
| Neppe, VM | 1 |
| Korczyn, AD; Shavit, S; Shlosberg, I | 1 |
| Ishide, N | 1 |
| Borowicz, KK; Czuczwar, SJ; Gasior, M; Kleinrok, Z | 1 |
| Rosini, JM; Whyte, CJ | 1 |
| Ashna, A; Dos Remedios, C; Laver, DR; Molenaar, P; van Helden, DF | 1 |
| Broomall, E; Ritter, DM; Tian, C | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Duncton, MA; Emerling, DE; Kelly, MG; Nguyen, MT; Vincent, F | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
2 review(s) available for phenytoin and dantrolene
| Article | Year |
|---|---|
Intracellular calcium modulators for cardiac muscle in pathological conditions.
Topics: Animals; Anti-Arrhythmia Agents; Anticonvulsants; Arrhythmias, Cardiac; Benzothiazoles; Caffeine; Calcium; Calcium Channel Blockers; Dantrolene; Flunarizine; Homeostasis; Humans; Magnesium; Models, Cardiovascular; Muscle Relaxants, Central; Myocardial Contraction; Myocardium; Phenytoin; Piperidines; Ryanodine; Sarcoplasmic Reticulum; Thiazepines; Thiazoles | 1996 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
11 other study(ies) available for phenytoin and dantrolene
| Article | Year |
|---|---|
The cardiovascular effects of dantrolene sodium in dogs.
Topics: Animals; Blood Pressure; Cardiac Output; Central Venous Pressure; Dantrolene; Dogs; Electrocardiography; Heart; Heart Rate; Hydantoins; Injections, Intravenous; Phenytoin; Sodium Chloride | 1975 |
The neuroleptic malignant syndrome. A priority system.
Topics: Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Bromocriptine; Consciousness Disorders; Dantrolene; Fever; Humans; Muscle Rigidity; Phenytoin; Syndrome | 1984 |
The chick as a model for malignant hyperpyrexia.
Topics: Animals; Calcium; Chickens; Dantrolene; Disease Models, Animal; Drug Evaluation, Preclinical; Malignant Hyperthermia; Phenytoin; Poultry Diseases; Procaine; Succinylcholine | 1980 |
Influence of isradipine, niguldipine and dantrolene on the anticonvulsive action of conventional antiepileptics in mice.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Anticonvulsants; Calcium Channel Agonists; Calcium Channel Blockers; Carbamazepine; Dantrolene; Dihydropyridines; Disease Models, Animal; Drug Interactions; Electroshock; Epilepsy; Female; Isradipine; Lethal Dose 50; Mice; Motor Activity; Phenobarbital; Phenytoin; Random Allocation; Seizures; Valproic Acid | 1997 |
Dantrolene for Treatment of Suspected Neuroleptic Malignant Syndrome.
Topics: Analgesics, Opioid; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Dantrolene; Diagnosis, Differential; Fentanyl; Haloperidol; Humans; Levetiracetam; Male; Middle Aged; Neuroleptic Malignant Syndrome; Olanzapine; Phenytoin; Piracetam | 2018 |
Phenytoin Reduces Activity of Cardiac Ryanodine Receptor 2; A Potential Mechanism for Its Cardioprotective Action.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Calcium; Calcium Channel Blockers; Cardiotonic Agents; Dantrolene; Dose-Response Relationship, Drug; Extracellular Vesicles; Heart Failure; Humans; Lipid Bilayers; Myocytes, Cardiac; Phenytoin; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Sheep | 2020 |
Treatment of SCN4A-induced myotonic crisis.
Topics: Dantrolene; Diazepam; Humans; Male; Muscle Relaxants, Central; Myotonia; NAV1.4 Voltage-Gated Sodium Channel; Phenytoin; Sodium Channel Blockers; Young Adult | 2021 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
Topics: Amidohydrolases; Carbamates; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Piperazines; Stereoisomerism; Structure-Activity Relationship | 2009 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |